Inotiv, Inc. to Report Second Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
Inotiv, Inc. (NASDAQ: NOTV) will release its fiscal 2021 second quarter financial results on May 5, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. Eastern Time. Interested participants can join via phone or through a live webcast on the company's website. Inotiv specializes in nonclinical and analytical drug discovery services, supporting both emerging and leading pharmaceutical companies. The release also includes a forward-looking statement warning of various market risks and uncertainties.
- Company specializes in nonclinical and analytical drug development.
- Expected earnings call provides transparency on fiscal performance.
- Forward-looking statements highlight potential risks and uncertainties impacting market demand and operations.
- COVID-19 pandemic noted as a risk factor for business operations.
WEST LAFAYETTE, Ind., April 26, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company will issue its financial results press release for the fiscal 2021 second quarter ended March 31, 2021, on Wednesday, May 5, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate on the call by dialing:
- (877) 407-9753 (Domestic)
- (201) 493-6739 (International)
The live conference call webcast will be accessible in the Investors section of the Company’s website and directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/bas2/mediaframe/44705/indexl.html
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s website at: https://www.inotivco.com/investors/investor-information/.
About the Company
Inotiv, Inc. is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | The Equity Group Inc. | |
| Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA | |
| (765) 497-8381 | (212) 836-9614 | |
| btaylor@inotivco.com | kahl@equityny.com | |
| Devin Sullivan | ||
| (212) 836-9608 | ||
| dsullivan@equityny.com |
FAQ
When will Inotiv release its Q2 2021 financial results?
What time is Inotiv's earnings conference call scheduled?
How can I participate in Inotiv's earnings call?
What are the risks mentioned in Inotiv's press release?
Where can I find the replay of Inotiv's earnings call?
